Development and Validation of a High-Performance Liquid Chromatographic Method for the Determination of Cinitapride in Human Plasma

Table 5

Stability studies.

Stability	Spiked final concentration (g/mL)	Mean ± SD	%CV	%nominal	%RE
BT	3	2.79 ± 0.10	3.47	93.05	−6.95
	15	14.52 ± 0.22	1.51	96.79	−3.20
	35	33.83 ± 0.49	1.45	96.65	−3.35
ST	35	32.82 ± 0.68	3.61	93.78	−6.22
LT	35	33.22	2.52	94.90	−5.10
FT	3	2.78 ± 0.08	3.09	2.78	−7.22
	10	9.59 ± 0.25	2.63	95.90	−4.10
	25	24.46 ± 0.18	0.73	97.84	−2.16
DI	14	13.55 ± 0.28	2.04	96.80	−3.20
	7	6.82 ± 0.11	1.65	97.38	−2.62

BT: bench-top stability, 6 hrs; ST: short-term stability, 6 hrs; LT: long-term stability, 35 days; FT: freeze-thaw stability, 3 cycles; DI: dilution integrity.